247 related articles for article (PubMed ID: 32460887)
1. Early discontinuation of empirical antibiotic treatment in neutropenic patients with acute myeloid leukaemia and high-risk myelodysplastic syndrome.
Niessen FA; van Mourik MSM; Bruns AHW; Raijmakers RAP; de Groot MCH; van der Bruggen T
Antimicrob Resist Infect Control; 2020 May; 9(1):74. PubMed ID: 32460887
[TBL] [Abstract][Full Text] [Related]
2. Safety and risk of febrile recurrence after early antibiotic discontinuation in high-risk neutropenic patients with haematological malignancies: a multicentre observational study.
Paret R; Le Bourgeois A; Guillerm G; Tessoulin B; Rezig S; Gastinne T; Couturier MA; Boutoille D; Lecomte R; Ader F; Le Gouill S; Ansart S; Talarmin JP; Gaborit B
J Antimicrob Chemother; 2022 Aug; 77(9):2546-2556. PubMed ID: 35748614
[TBL] [Abstract][Full Text] [Related]
3. Guidance of empirical antimicrobial therapy by surveillance cultures in high-risk neutropenic patients: a retrospective cohort study.
de la Court JR; Heijmans J; Huynh J; Sieswerda E; de Jonge NA; van Dijk K; Sigaloff KCE; Schade RP
Antimicrob Resist Infect Control; 2022 Dec; 11(1):160. PubMed ID: 36529742
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of early de-escalation of empiric antimicrobial therapy in acute leukemia patients with febrile neutropenia at a large academic medical center.
Ly WJ; Brown EE; Pedretti Z; Auten J; Wilson WS
J Oncol Pharm Pract; 2023 Mar; 29(2):305-310. PubMed ID: 34927495
[TBL] [Abstract][Full Text] [Related]
5. A change for the antibacterial treatment policy to decrease carbapenem consumption at a haematopoietic stem cell transplantation centre.
Metan G; Kaynar L; Yozgat N; Elmali F; Kürkçüoglu CA; Alp E; Çetin M
Infez Med; 2017 Mar; 25(1):33-37. PubMed ID: 28353453
[TBL] [Abstract][Full Text] [Related]
6. Decrease in vancomycin-resistant Enterococcus colonization associated with a reduction in carbapenem use as empiric therapy for febrile neutropenia in patients with acute leukemia.
Ford CD; Coombs J; Stofer MG; Lopansri BK; Webb BJ; Ostronoff F; Asch J; Hoda D
Infect Control Hosp Epidemiol; 2019 Jul; 40(7):774-779. PubMed ID: 31046849
[TBL] [Abstract][Full Text] [Related]
7. Short versus extended treatment with a carbapenem in patients with high-risk fever of unknown origin during neutropenia: a non-inferiority, open-label, multicentre, randomised trial.
de Jonge NA; Sikkens JJ; Zweegman S; Beeker A; Ypma P; Herbers AH; Vasmel W; de Kreuk A; Coenen JLLM; Lissenberg-Witte B; Kramer MHH; van Agtmael MA; Janssen JJWM
Lancet Haematol; 2022 Aug; 9(8):e563-e572. PubMed ID: 35691326
[TBL] [Abstract][Full Text] [Related]
8. Piperacillin-tazobactam versus carbapenem therapy with and without amikacin as empirical treatment of febrile neutropenia in cancer patients: results of an open randomized trial at a university hospital.
Oztoprak N; Piskin N; Aydemir H; Celebi G; Akduman D; Keskin AS; Gokmen A; Engin H; Ankarali H
Jpn J Clin Oncol; 2010 Aug; 40(8):761-7. PubMed ID: 20427546
[TBL] [Abstract][Full Text] [Related]
9. Antimicrobial Stewardship in a Hematological Malignancy Unit: Carbapenem Reduction and Decreased Vancomycin-Resistant Enterococcus Infection.
Webb BJ; Majers J; Healy R; Jones PB; Butler AM; Snow G; Forsyth S; Lopansri BK; Ford CD; Hoda D
Clin Infect Dis; 2020 Aug; 71(4):960-967. PubMed ID: 31751470
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of an antimicrobial stewardship intervention for early adaptation of antibiotic therapy in high-risk neutropenic patients.
Durand C; Risso K; Loschi M; Retur N; Emery A; Courjon J; Cluzeau T; Carles M
Antimicrob Resist Infect Control; 2024 Jan; 13(1):5. PubMed ID: 38233960
[TBL] [Abstract][Full Text] [Related]
11. Discontinuation of empirical antibiotic therapy in neutropenic acute myeloid leukaemia patients with fever of unknown origin: is it ethical?
Micol JB; Chahine C; Woerther PL; Ghez D; Netzer F; Dufour C; Merad M; Blot F; Chachaty E; de Botton S; Gachot B
Clin Microbiol Infect; 2014 Jul; 20(7):O453-5. PubMed ID: 24313354
[TBL] [Abstract][Full Text] [Related]
12. Early discontinuation of empirical antibacterial therapy in febrile neutropenia: the ANTIBIOSTOP study.
Le Clech L; Talarmin JP; Couturier MA; Ianotto JC; Nicol C; Le Calloch R; Dos Santos S; Hutin P; Tandé D; Cogulet V; Berthou C; Guillerm G
Infect Dis (Lond); 2018 Jul; 50(7):539-549. PubMed ID: 29451055
[TBL] [Abstract][Full Text] [Related]
13. Clinical characteristics and outcomes of Pseudomonas aeruginosa bacteremia in febrile neutropenic children and adolescents with the impact of antibiotic resistance: a retrospective study.
Kim HS; Park BK; Kim SK; Han SB; Lee JW; Lee DG; Chung NG; Cho B; Jeong DC; Kang JH
BMC Infect Dis; 2017 Jul; 17(1):500. PubMed ID: 28716109
[TBL] [Abstract][Full Text] [Related]
14. Evaluating Initial Empiric Therapy for Neutropenic Fever in Vancomycin-Resistant Enterococcus-Colonized Patients.
Snyder M; Pasikhova Y; Baluch A
Cancer Control; 2021; 28():10732748211045593. PubMed ID: 34558349
[TBL] [Abstract][Full Text] [Related]
15. Piperacillin/tazobactam plus amikacin versus carbapenem monotherapy as empirical treatment of febrile neutropenia in childhood hematological malignancies.
Yildirim I; Aytac S; Ceyhan M; Cetin M; Tuncer M; Cengiz AB; Secmeer G; Yetgin S
Pediatr Hematol Oncol; 2008 Jun; 25(4):291-9. PubMed ID: 18484473
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of repeat blood cultures during febrile neutropenia in adult acute myeloid leukaemia patients undergoing intensive chemotherapy.
Kimura SI; Gomyo A; Hayakawa J; Tamaki M; Akahoshi Y; Harada N; Ugai T; Kusuda M; Kameda K; Wada H; Ishihara Y; Kawamura K; Sakamoto K; Sato M; Terasako-Saito K; Kikuchi M; Nakasone H; Kako S; Tanihara A; Kanda Y
Infect Dis (Lond); 2017 Oct; 49(10):748-757. PubMed ID: 28631944
[TBL] [Abstract][Full Text] [Related]
17. Low utilization of vancomycin in febrile neutropenia: real-world evidence from 4 Brazilian centers.
Ramos JF; Pereira AD; Seiwald MCN; Gandolpho LS; Molla VC; Guaraná M; Nouér SA; Nucci M; Rodrigues CA
Support Care Cancer; 2023 Nov; 31(12):687. PubMed ID: 37947888
[TBL] [Abstract][Full Text] [Related]
18. Analysis of blood stream infections, antibiograms and clinical outcomes in haematological patients with febrile neutropenia: data from a tertiary care haematology institute in India.
Ghosh S; Chakraborty M; Samanta S; Sinha N; Saha S; Chattopadhyay A; Roy SS; Bhattacharyya M
Ann Hematol; 2021 Feb; 100(2):395-403. PubMed ID: 33140134
[TBL] [Abstract][Full Text] [Related]
19. Discontinuation of antimicrobial therapy in adult neutropenic haematology patients: A prospective cohort.
Van de Wyngaert Z; Berthon C; Debarri H; Bories C; Bonnet S; Nudel M; Carpentier B; Legrand C; Barbieux S; Chauvet P; Simonnet A; Willaume A; Bossard JB; Renaud L; Wattebled KJ; Escure G; Branche N; Arib I; Titecat M; Quesnel B; Alfandari S
Int J Antimicrob Agents; 2019 Jun; 53(6):781-788. PubMed ID: 30831232
[TBL] [Abstract][Full Text] [Related]
20. De-escalation and discontinuation strategies in high-risk neutropenic patients: an interrupted time series analyses of antimicrobial consumption and impact on outcome.
la Martire G; Robin C; Oubaya N; Lepeule R; Beckerich F; Leclerc M; Barhoumi W; Toma A; Pautas C; Maury S; Akrout W; Cordonnier-Jourdin C; Fihman V; Venditti M; Cordonnier C
Eur J Clin Microbiol Infect Dis; 2018 Oct; 37(10):1931-1940. PubMed ID: 30051357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
